Epidemiological Insights into Invasive Fungal Rhinosinusitis among COVID-19 Inpatients: Unveiling Diverse Pathogens with implications on cancer patients

The emergence of invasive fungal rhinosinusitis (IFRS), as well as COVID-19 at the same time, poses a challenge to patients receiving treatment in hospitals. Research have shown various infections caused by fungi that relate to the epidemiology of invasive fungal rhinosinusitis among patients suffering from COVID-19. In this retrospective analysis, examined mycological investigations, subject characteristics, clinical manifestations, antifungal drugs used and length of illness among 68 patients diagnosed with Acute Invasive Fungal Rhino-Sinusitis (AIFRS). The research results indicated that steroid therapy was applied in 32.81% of cases and more than half of examines were men. The necessity for early detection is highlighted by the variety of clinical symptoms of headaches (22.40%). Tissue culture, histological analysis and molecular identification of culture isolates were all part of the mycological research. Amphotericin B (30.21%) and Nystatin (22.40%) were the antifungal drugs utilized, indicating a customized approach to therapy. The length of the disease varied by 22.92% of patients reported symptoms lasting between 16 and 30 days. The age distribution showed that the 50 to 59 age group accounted for a significant amount (13.02%). The research highlights the vital need for caution while identifying and treating AIFRS in COVID-19 inpatients, with a focus on a variety of infections and specialized treatment modalities.